20/20 BioLabs announces a standstill agreement limiting Series E Preferred Stock conversions, reducing potential dilution for common stock.
Quiver AI Summary
20/20 BioLabs, Inc. has announced a standstill agreement with Streeterville Capital, LLC regarding its outstanding Series E Convertible Preferred Stock, effective July 16, 2026. This agreement places a temporary restriction on the conversion of these preferred shares into common stock, allowing conversion only when the stock trades at least 10% above a defined minimum price for a 120-day period. This measure aims to mitigate potential dilution of the company’s common shares while maintaining both parties' existing rights under the related transaction documents. After the standstill period, Streeterville may resume conversions per the original terms. Further details will be provided in a forthcoming SEC filing. 20/20 BioLabs specializes in AI-powered blood tests for early cancer detection and chronic disease prevention.
Potential Positives
- Agreement with Streeterville Capital temporarily restricts conversions of Series E Preferred Stock, helping to mitigate potential near-term dilution of common stock.
- Preserves existing rights and obligations of both parties, ensuring stability during the standstill period.
- Demonstrates proactive management of the company’s capital structure, potentially enhancing shareholder confidence.
- Reinforces the company's commitment to maintaining a strong market position as an early entrant in AI-powered blood tests for cancer and chronic diseases.
Potential Negatives
- The standstill agreement may signal to investors that the company is facing pressures related to its stock price and capital structure, potentially impacting investor confidence.
- The restriction on conversions below a defined price threshold might indicate financial instability or difficulties in meeting investor expectations, raising concerns about the company's short-term viability.
- The temporary nature of the agreement suggests that the company is currently unable to prevent dilution in the long term, which could be detrimental to shareholder value once the standstill period concludes.
FAQ
What is the purpose of the standstill agreement announced by 20/20 BioLabs?
The standstill agreement temporarily restricts conversions of Series E Preferred Stock to mitigate potential near-term dilution.
When did the standstill agreement become effective?
The standstill agreement became effective on July 16, 2026.
How long will the standstill period last?
The standstill period will last for 120 days from the effective date of the agreement.
What conditions must be met for Streeterville to convert Series E Preferred Stock?
Streeterville can only convert shares if the common stock trades at least 10% above the defined Minimum Price on a given trading day.
Where can I find more information about the agreement?
Additional information will be provided in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AIDX Revenue
$AIDX had revenues of $353.4K in Q1 2026.
You can track AIDX financials on Quiver Quantitative's AIDX stock page.
You can access data on AIDX stock through the Quiver Quantitative API.
$AIDX Hedge Fund Activity
We have seen 6 institutional investors add shares of $AIDX stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CRESSET ASSET MANAGEMENT, LLC added 264,368 shares (+inf%) to their portfolio in Q1 2026, for an estimated $497,011
- CITADEL ADVISORS LLC added 16,227 shares (+inf%) to their portfolio in Q1 2026, for an estimated $30,506
- XTX TOPCO LTD added 10,329 shares (+inf%) to their portfolio in Q1 2026, for an estimated $19,418
- UBS GROUP AG added 8,314 shares (+inf%) to their portfolio in Q1 2026, for an estimated $15,630
- MAI CAPITAL MANAGEMENT added 1,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,880
- TOTH FINANCIAL ADVISORY CORP removed 57 shares (-36.3%) from their portfolio in Q2 2026, for an estimated $31
- ALLWORTH FINANCIAL LP added 30 shares (+inf%) to their portfolio in Q1 2026, for an estimated $56
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$AIDX Price Targets
Multiple analysts have issued price targets for $AIDX recently. We have seen 3 analysts offer price targets for $AIDX in the last 6 months, with a median target of $2.0.
Here are some recent targets:
- Michael Okunewitch from Maxim Group set a target price of $5.0 on 05/11/2026
- David Kwan from TD Cowen set a target price of $1.75 on 04/02/2026
- Kevin Krishnaratne from Scotiabank set a target price of $2.0 on 02/04/2026
Full Release
Agreement Temporarily Restricts Preferred-to-Common Stock Conversions Below a Defined Price Threshold, Mitigating Potential Near-Term Dilution
GAITHERSBURG, Md., July 23, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today announced that it has entered into a standstill agreement (the “Agreement”) with Streeterville Capital, LLC (“Streeterville”) relating to the Company’s outstanding Series E Convertible Preferred Stock (the “Series E Preferred Stock”). The Agreement became effective on July 16, 2026.
Under the terms of the Agreement, during the 120-day period beginning on the date of the Agreement, Streeterville has agreed not to convert any shares of Series E Preferred Stock into shares of the Company’s common stock unless, on a given trading day, the common stock trades at a price at least 10% above the “Minimum Price” (as defined under Nasdaq Rule 5635) (the “Standstill”) provided that the Standstill shall terminate immediately upon the occurrence of any breach of the Agreement or any Event of Default (as defined in the Certificate of Designation for the Series E Preferred Stock). The Agreement temporarily limits potential dilution from conversions of the Series E Preferred Stock while preserving the existing rights and obligations of both parties under the related transaction documents.
Upon expiration or termination of the Standstill, Streeterville may resume converting shares of the Series E Preferred Stock in accordance with the terms of the applicable transaction documents. Except as expressly provided in the Agreement, the Series E Preferred Stock and all related transaction documents remain in full force and effect.
Additional information regarding the Agreement will be included in a Current Report on Form 8-K to be filed with the U.S. Securities and Exchange Commission.
About 20/20 BioLabs
20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection, or MCED, blood test, and OneTest™ for Longevity measures inflammatory biomarkers and is commercially available. OneTest’s affordable, accurate, accessible tests can be conveniently utilized at home using new, upper-arm capillary collection devices that avoid painful needles. Tests are run in the Company’s College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.
For more information visit https://2020biolabs.com .
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements regarding the expected effects of the Agreement, including its anticipated impact on conversion activity, dilution and the trading market for the Company’s common stock, as well as the Company’s business strategy and prospects. These statements are often identified by words such as “believe,” “expect,” “intend,” “anticipate,” “plan,” “may,” “will,” “should” and similar expressions. Forward-looking statements are based on management’s current expectations and assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied. There can be no assurance that the Agreement will have the intended effects, that the standstill will not terminate early, or that Streeterville will not convert shares of Series E Preferred Stock following the standstill period. Additional factors are described in the Company’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and subsequent reports. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Investor Relations
Chris Tyson
MZ Group
Direct: 949-491-8235
[email protected]
